Journal
ANTI-CANCER DRUGS
Volume 20, Issue 9, Pages 848-849Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/CAD.0b013e32832fffc7
Keywords
end stage renal disease; renal cell carcinoma; sunitinib
Categories
Ask authors/readers for more resources
Sunitinib is a tyrosine kinase inhibitor with a low toxicity profile and proven activity against metastatic renal cell carcinoma (mRCC). However, there is very limited data on the effect of sunitinib on end stage renal disease owing to mRCC. We report our experience with the use of sunitinib in a patient with mRCC and end stage renal disease undergoing hemodialysis. Anti-Cancer Drugs 20:848-849 (C) 2009 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
